Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR exon 19 deletion + PD-L1 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR exon 19 deletion + PD-L1 overexpression	Non Small Cell Lung Cancer	EGFR exon 19 deletion + PD-L1 overexpression	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	atezolizumab + afatinib Sensitive: C4 – Case Studies atezolizumab + afatinib Sensitive : C4	atezolizumab + afatinib Sensitive: C4 – Case Studies atezolizumab + afatinib Sensitive : C4
EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	gefitinib Resistant: C4 – Case Studies gefitinib Resistant : C4	gefitinib Resistant: C4 – Case Studies gefitinib Resistant : C4
EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4